Sociedad Americana de Hirudoterapia

Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: up-regulation by interleukin-1beta and glucocorticoids

Research article published in Arthritis and rheumatism (2004)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Research reportGenómica y proteómicaToh ML et al. · Arthritis and rheumatism, 2004

Abstract

OBJECTIVE: Mitogen-activated protein kinases (MAPKs) are activated by proinflammatory stimuli. MAPK phosphatases (MKPs), in particular MKP-1, have been identified as endogenous negative regulators of MAPK activation. Since MAPKs are known to be important in rheumatoid arthritis (RA) synoviocyte activation, this study assessed the expression, regulation, and function of MKP-1 in RA. METHODS: MKP-1 expression was measured by Western blotting (WB) and real-time polymerase chain reaction (PCR). RA fibroblast-like synoviocytes (FLS) were treated with interleukin-1beta (IL-1beta), tumor necrosis factor alpha, fetal calf serum, and dexamethasone. Expression of MAPKs in RA FLS was analyzed by WB using phosphospecific antibodies, while IL-6 expression was assessed by real-time PCR. RESULTS: MKP-1 protein and messenger RNA were detected in cultured RA FLS. IL-1beta rapidly up-regulated MKP-1, coinciding with reciprocal down-regulation of ERK, JNK, and p38 MAPK phosphorylation. Dexamethasone rapidly and sustainably up-regulated MKP-1, and this also coincided with down-regulation of ERK, JNK, and p38 MAPK phosphorylation. In addition, dexamethasone augmented IL-1beta-induced up-regulation of MKP-1, and this was associated with inhibition of ERK, JNK, and p38 MAPK phosphorylation and IL-6 expression. Dexamethasone had no effect on the phosphorylation of upstream kinases such as MEKK-3/6. In the presence of glucocorticoid (GC) receptor antagonist RU 486, the dexamethasone-mediated up-regulation of MKP-1 was impaired. Moreover, inhibition of MKP-1 expression impaired dexamethasone-mediated inhibition of MAPK phosphorylation. CONCLUSION: This study demonstrates the expression of MKP-1 in RA FLS. Cytokine and GC regulation of MKP-1 may be important in determining the magnitude of the inflammatory response in RA that is mediated via MAPKs. The effects of GCs in RA may be mediated, in part, via GC receptor-dependent up-regulation of MKP-1.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsArthritis, RheumatoidBlotting, WesternCells, CulturedDexamethasoneDual Specificity Phosphatase 1GlucocorticoidsHumansInterleukin-1MifepristoneMitogen-Activated Protein KinasesPhosphorylationPolymerase Chain Reaction

Resumen

Mitogen-activated protein kinases (MAPKs) are activated by proinflammatory stimuli.

Por qué esto importa para la hirudoterapia

Este estudio examinó la expresión, regulación y función de la fosfatasa-1 de MAPK (MKP-1) en sinoviocitos tipo fibroblasto de artritis reumatoide (AR) cultivados, encontrando que la interleucina-1beta y la dexametasona regulan al alza MKP-1, con una regulación a la baja recíproca de la fosforilación de ERK, JNK y p38 MAPK. Este trabajo dilucida vías de señalización inflamatoria en sinoviocitos de AR que podrían, en principio, solaparse con mecanismos relevantes para los efectos antiinflamatorios atribuidos a factores derivados de sanguijuela en contextos de medicina complementaria. Sin embargo, no se mencionan en ningún lugar del resumen sanguijuelas, hirudoterapia, componentes del secretoma de la sanguijuela ni ninguna sustancia derivada de sanguijuela. Por lo tanto, la relevancia para el ámbito de ASH es esencialmente inexistente basándose únicamente en este resumen.

Citación

Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: up-regulation by interleukin-1beta and glucocorticoids

Toh ML et al. · Arthritis and rheumatism, 2004

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.